Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia

World Journal of Biological Psychiatry

Volumn 6, Issue 2, 2005, Pages 69-84

  Wiltfang, Jens ^a,b   Lewczuk, P ^a,b   Riederer, P ^c   Grunblatt E ^c   Hock, C ^d   Scheltens, P ^e   Hampel, H ^f   Vanderstichele, H ^g   Iqbal, K ^h   Galasko, D ⁱ   Lannfelt, L ^j   Otto, M ^k   Esselmann, H ^k   Henkel, A W ^a   Kornhuber, J ^k   Blennow, K ^l  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Center for Clinical Neuroproteomics   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g INNOGENETICS   (Belgium)

^h NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UPPSALA UNIVERSITY   (Sweden)

^k UNIVERSITY OF GÖTTINGEN   (Germany)

^l SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Dementia; Neuroinflammation

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CELL PROTEIN; IRON BINDING PROTEIN; MICROSPHERE; MONOCLONAL ANTIBODY; NEURONAL THREAD PROTEIN; PROTEIN P97; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; BLOOD ANALYSIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; COMPUTER PROGRAM; CONSENSUS DEVELOPMENT; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; FLUORESCENCE CORRELATION SPECTROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENOTYPE; HUMAN; INFLAMMATORY DISEASE; LIFE EXPECTANCY; LYME DISEASE; MULTIPLE SCLEROSIS; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYMPTOMATOLOGY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CONSENSUS; DIAGNOSIS, DIFFERENTIAL; GENOTYPE; HUMANS; IMMUNOBLOTTING; MICROTUBULE-ASSOCIATED PROTEINS; NEURONS; PHOSPHORYLATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TAU PROTEINS; TIME FACTORS;

EID: 21244457198     PISSN: 15622975     EISSN: None     Source Type: Journal    
DOI: 10.1080/15622970510029786     Document Type: Review

References (134)

1. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B. 1980. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27:1029-1034.
2. Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B. 1987. Histopathological criteria for progressive dementia disorders: Clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol (Berlin) 74:209-225.
3. Alexopoulos GS, Young RC, Lieberman KW, Shamoian CA. 1987. Platelet MAO activity in geriatric patients with depression and dementia. Am J Psychiatry 144:1480-1483.
4. Andreasen N, Minthon L, Clarberg A, Davidsson P, Gotffries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. 1999. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53:1488-1494.
5. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. 2001. Evaluation of CSF-tau and CSF-Ab42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58:373-379.
6. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. 2003. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl 179:47-51.
7. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, Seiki H, Takase S, Clark CM, Lee VM et al. 1995. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 38:649-652.
8. Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H, Sasaki H, Imahori K. 2000. CSF phosphorylated tau protein and mild cognitive impairment: A prospective study. Exp Neurol 166:201-203.
9. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. 1992. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631-639.
10. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. 2002. Specifc tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (Berlin) 103:26-35.
11. Baas PW, Pienkowski TP, Kosik KS. 1991. Processes induced by tau expression in Sf9 cells have an axon-like microtubule organization. J Cell Biol 115:1333-1344.
12. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E. 2002. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 110:1-7.
13. Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W, Masters CL. 1993. Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. Ann NY Acad Sci 695:91-102.
14. Blennow K, Wallin A, Hager O. 1993. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 88:221-223.
15. Blennow K, Vanmechelen E, Hampel H. 2001. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24:87-97.
16. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. 1996. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett 214:163-166.
17. Bongioanni P, Gemignani F, Boccardi B, Borgna M, Rossi B. 1997. Platelet monoamine oxidase molecular activity in demented patients. Ital J Neurol Sci 18:151-156.
18. Bonuccelli U, Piccini P, Marazziti D, Cassano GB, Muratorio A. 1990. Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease. J Neural Transm Park Dis Dement Sect 2:139-147.
19. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berlin) 82:239-259.
20. Brown AM, Tummolo DM, Rhodes KJ, Hofmann JR, Jacobsen JS, Sonnenberg-Reines J. 1997. Selective aggregation of endogenous beta-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc. J Neurochem 69:1204-1212.
21. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. 2000. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95-130.
22. Buerger K, Zinkowski R, Teipel S.J, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttilä T, Schapiro MB, Rapoport SI, Möller HJ, Davies P, Hampel H. 2002. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59:1267-1272.
23. Buerger K, Zinkowski R, Teipel SJ, Arai H, DeBernardis J, Kerkman D, McCulloch C, Padberg F, Faltraco F, Goernitz A, Tapiola T, Rapoport SI, Pirttila T, Moller HJ, Hampel H. 2003. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry 160:376-379.
24. Bullock R. 2002. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry 180:135-139.
25. Damberg M, Garpenstrand H, Hallman J, Oreland L. 2001. Genetic mechanisms of behavior: Don't forget about the transcription factors. Mol Psychiatry 6:503-510.
26. Danielczyk W, Streifler M, Konradi C, Riederer P, Moll G. 1988. Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand 78:730-736.
27. Dawson HN, Ferreira A, Eyster M.V, Ghoshal N, Binder LI, Vitek MP. 2001. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114:1179-1187.
28. de la Monte SM, Volicer L, Hauser SL, Wands JR. 1992. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 32:733-742.
29. de la Monte SM, Wands JR. 1992. Neuronal thread protein overexpression in brains with Alzheimer's disease lesions. J Neurol Sci 113:152-164.
30. Eigen M, Rigler R. 1994. Sorting single molecules: application to diagnostics and evolutionary biotechnology. Proc Natl Acad Sci USA 91:5740-5747.
31. Eikelenboom P, Rozemuller AJ, Hoozemans JJ, Veerhuis R, van Gool WA. 2000. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis Assoc Disord 14:S54-61.
32. Ekblom J, Garpenstrand H, Damberg M, Chen K, Shih JC, Oreland L. 1998. Transcription factor binding to the core promoter of the human monoamine oxidase B gene in the cerebral cortex and in blood cells. Neurosci Lett 258:101-104.
33. Fallon BA, Nields JA. 1994. Lyme disease: A neuropsychiatric illness. Am J Psychiatry 151:1571-1583.
34. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. J Am Med Assoc 278:1349-1356.
35. Fischer P, Gotz ME, Ellinger B, Streifler M, Riederer P, Danielczyk W. 1994. Platelet monoamine oxidase B activity and vitamin B12 in dementia. Biol Psychiatry 35:772-774.
36. Fischer P, Jungwirth S, Krampla W, Weissgram S, Kirchmeyr W, Schreiber W, Huber K, Rainer M, Bauer P, Tragl KH. 2002. Vienna Transdanube Aging 'VITA': Study design, recruitment strategies and level of participation. J Neural Transm Suppl 105-116.
37. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ. 2003. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the Biological Markers Working Group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 24:521-536.
38. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. 1999. The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport 10:1699-1705.
39. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. 1998. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55:937-945.
40. Golombowski S, Muller-Spahn F, Romig H, Mendla K, Hock C. 1997. Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett 225:213-215.
41. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A, Oreland L, Svennerholm L, Wiberg A, Winblad B. 1983. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 4:261-271.
42. Götz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M, Muller F, Danielczyk W. 1998. Platelet monoamine oxidase B activity in dementia. A 4-year follow-up. Dement Geriatr Cogn Disord 9:74-77.
43. Greenawalt JW, Schnaitman C. 1970. An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria. J Cell Biol 46:173-179.
44. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. 1986. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83:4913-4917.
45. Hampel H, Buerger K, Kohnken R, Teipel SJ, Zinkowski R, Moeller HJ, Rapoport SI, Davies P. 2001. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 49:545-546.
46. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K. 2004. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61:95-102.
47. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T, Hirokawa N. 1994. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369:488-491.
48. Harper JD, Lansbury PT. Jr. 1997. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66:385-407.
49. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. 2001. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297:187-190.
50. Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K, Wang J. 2002. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: An ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 160:1269-1278.
51. (1-42) and tau levels in CSF. Neurology 52:1555-1562.
52. Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, Wisniewski HM, Alafuzoff I, Winblad B. 1986. Defective brain microtubule assembly in Alzheimer's disease. Lancet ii:421-426.
53. Iqbal K, Alonso Adel C, El-Akkad E, Gong CX, Haque N, Khatoon S, Pei JJ, Tsujio I, Wang JZ, Grundke-Iqbal I. 2002. Signifcance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J Mol Neurosci 19:95-99.
54. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, Wiltfang J, Otto M, Kretzschmar H, Moeller HJ, Imagawa M, Kohno H, Nakashima K, Kuzuhara S, Sasaki H, Imahori K. 2001. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 50:150-156.
55. Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. 1991. Monoamine oxidase B in brains from patients with Alzheimer's disease: A biochemical and autoradiographical study. Neuroscience 45:1-12.
56. 1-42(43) in Alzheimer's disease: A study in Japan. Ann Neurol 44:17-26.
57. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736.
58. Karp NA, Kreil DP, Lilley KS. 2004. Determining a significant change in protein expression with DeCyder during a pair-wise comparison using two-dimensional difference gel electrophoresis. Proteomics 4:1421-1432.
59. Kennard ML, Feldman H, Yamada T, Jefferies WA. 1996. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med 2:1230-1235.
60. Knopman D. 2001. Pharmacotheraphy for Alzheimer's disease. Curr Neurol Neurosci Rep 1:428-434.
61. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC. 2001. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1143-1153.
62. Knops J, Kosik KS, Lee G, Pardee JD, Cohen-Gould L, McConlogue L. 1991. Overexpression of tau in a nonneuronal cell induces long cellular processes. J Cell Biol 114:725-733.
63. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Rüther E, Kornhuber J, Wiltfang J. 2003. The amyloid-b (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Ab peptide. Rapid Commun Mass Spectrom 17:1291-1296.
64. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J. 2004a. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: Original data and review of the literature. J Mol Neurosci 23:115-122.
65. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, Otto M, Kornhuber J, Wiltfang J. 2004b. Amyloid β peptides in cerebrospinal fluid as profied with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: Evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry 55:524-530.
66. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J. 2004c. Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol Aging 25:273-281.
67. Lewczuk P, Esselmann H, Bibl M, Paul S, Svitek J, Miertschischk J, Meyrer R, Smirnov A, Maler J.M, Klein C, Otto M, Bleich S, Sperling W, Kornhuber J, Rüther E, Wiltfang J. 2004d. Electrophoretic separation of amyloid β (Aβ) peptides in plasma. Electrophoresis 25:3336-3343.
68. Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J. 1996. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol 40:561-568.
69. Louis ED. 2003. Whipple disease. Curr Neurol Neurosci Rep 3:470-475.
70. Luer W, Poser S, Weber T, Jurgens S, Eichenlaub D, Pohle HD, Felgenhauer K. 1988. Chronic HIV encephalitis. I. Cerebrospinal fluid diagnosis. Klin Wochenschr 66:21-25.
71. Mawal-Dewan M, Henley J, Van de Voorde A, Trojanowski JQ, Lee VM. 1994. The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. J Biol Chem 269:30981-30987.
72. Mayeux R. 1998. Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiol Aging 19:139-143.
73. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH. 1998. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. New Engl J Med 338:506-511.
74. McGeer PL, McGeer EG. 2001. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22:799-809.
75. Merchant M, Weinberger SR. 2000. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21:1164-1177.
76. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R et al. 1995. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38:643-648.
77. Mulder C, Scheltens P, Visser JJ, van Kamp GJ, Schutgens RB. 2000. Genetic and biochemical markers for Alzheimer's disease: Recent developments. Ann Clin Biochem 37:593-607.
78. Nägga K, Gottfries J, Blennow K, Marcusson J. 2002. Cerebrospinal fluid phospho-tau, total tau and β-amyloid1-42 in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 14:183-190.
79. Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. 1990. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol (Berlin) 80:419-425.
80. National Institute on Aging Working Group. 1998. Consensus report of the Working Group on: 'Molecular and Biochemical Markers of Alzheimer's Disease'. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 19:109-116.
81. Navia BA, Price RW. 1987. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol 44:65-69.
82. Oreland L, Gotffries CG. 1986. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 10:533-540.
83. Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, Weber T, Kretzschmar HA, Poser S. 1997. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 225:210-212.
84. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, Kornhuber J, Kretzschmar HA, Poser S, Wiltfang J. 2000. Decreased β-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54:1099-1102.
85. Panegyres PK. 1997. The amyloid precursor protein gene: A neuropeptide gene with diverse functions in the central nervous system. Neuropeptides 31:523-535.
86. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena A, Lütjohann D, Ghebremedhin E, Hegi T, Pasch T, Träxler M, Brühl A, Benussi L, Binetti G, Braak H, Nitsch R.M, Hock C. 2003. Increased brain β-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 60:29-35.
87. Parnetti L, Reboldi GP, Santucci C, Santucci A, Gaiti A, Brunetti M, Cecchetti R, Senin U. 1994. Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging (Milano) 6:201-207.
88. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. 2001. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies., Phospho-Tau International Study Group. Neurol Sci 22:77-78.
89. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. 1999. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303-308.
90. Pitschke M, Prior R, Haupt M, Riesner D. 1998. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 4:832-834.
91. Poser S, Luer W, Eichenlaub D, Pohle HD, Weber T, Jurgens S, Felgenhauer K. 1988. Chronic HIV encephalitis. II. Clinical aspects. Klin Wochenschr 66:26-31.
92. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. 2001. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21:4183-4187.
93. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. 2002. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol 59:972-976.
94. Quality Standards Subcommittee of the American Academy of Neurology. 1994. Practice parameter for diagnosis and evaluation of dementia (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 44:2203-2206.
95. Rao SM. 1986. Neuropsychology of multiple sclerosis: A critical review. J Clin Exp Neuropsychol 8:503-542.
96. Reiber H, Ungefehr S, Jacobi C. 1998. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 4:111-117.
97. Reiber H. 2001. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173-186.
98. Reiber H, Peter JB. 2001. Cerebrospinal fluid analysis: Disease related data patterns and evaluation programs. J Neurol Sci 184:101-122.
99. Riederer P, Youdim MBH. 1993. The therapeutic place and value of present and future MAO-B inhibitors-L-deprenyl as the gold standard. In: Szelenyi J, editor. Inhibitors of monoamine oxidase B, pharmacology and clinical use in neurodegenerative disorders. Basel: Birkhäuser. p 327-338.
100. (1-42) in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 284:85-88.
101. Rosner H, Rebhan M, Vacun G, Vanmechelen E. 1995. Developmental expression of tau proteins in the chicken and rat brain: Rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. Int J Dev Neurosci 13:607-617.
102. Rovaris M, Filippi M. 2000. MRI correlates of cognitive dysfunction in multiple sclerosis patients. J Neurovirol 6(Suppl 2):S172-175.
103. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, Richards JG. 1994. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62:15-30.
104. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P. 2004. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62:1580-1584.
105. Selkoe DJ. 1994. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 10:373-403.
106. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K. 1998. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys 357:299-309.
107. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New Engl J Med 346:476-483.
108. Shahani N, Brandt R. 2002. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 59:1668-1680.
109. Singh TJ, Wang JZ, Novak M, Kontzekova E, Grundke-Iqbal I, Iqbal K. 1996. Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett 387:145-148.
110. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nagga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K. 2001. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values. Clin Chem 47:1776-1781.
111. Sjögren M, Gisslen M, Vanmechelen E, Blennow K. 2001. Low cerebrospinal fluid b-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett 314:33-36.
112. Smith RC, Ho BT, Kralik P, Vroulis G, Gordon J, Wolff J. 1982. Platelet monamine oxidase in Alzheimer's disease. J Gerontol 37:572-574.
113. Song W, Zhou LJ, Zheng SX, Zhu XZ. 2000. Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. Acta Pharmacol Sin 21:557-563.
114. Sparks DL, Woeltz VM, Markesbery WR. 1991. Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. Arch Neurol 48:718-721.
115. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. 2002. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156:1051-1063.
116. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993a. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977-1981.
117. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. 1993b. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102.
118. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM. 2003. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. J Am Med Assoc 289:2094-2103.
119. Takei Y, Teng J, Harada A, Hirokawa N. 2000. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol 150:989-1000.
120. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P. 2002. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23:237-243.
121. Tatebayashi Y, Haque N, Tung YC, Iqbal K, Grundke-Iqbal I. 2004. Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. J Cell Sci 117:1653-1663.
122. Tumani H, Nolker G, Reiber H. 1995. Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. Neurology 45:1663-1670.
123. Ujiie M, Dickstein DL, Jefferies WA. 2002. p97 as a biomarker for Alzheimer disease. Front Biosci 7:E42-47.
124. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, Andreasen N, Blennow K. 2000. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49-52.
125. Vanmechelen E, Van Kerschaver E, Blennow K, De Deyn PP, Galasko D, Parnetti L, Sindic CJM, Arai H, Riemenschneider M, Hampel H, Pottel H, Valgaeren A, Hulstaert F, Vanderstichele H. 2001. CSF-Phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies in Alzheimer's disease. In: Iqbal K, Sisodia SS, Winblad B, editors. Advances in etiology, pathogenesis and therapeutics. Chichester: John Wiley and Sons Ltd. p 285-291.
126. Vignali DA. 2000. Multiplexed particle-based flow cytometric assays. J Immunol Methods 243:243-255.
127. Weyler W, Hsu YP, Breakefield XO. 1990. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47:391-417.
128. Wiltfang J, Arold N, Neuhoff V. 1991. A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100,000-1000, and their detection with picomolar sensitivity. Electrophoresis 12:352-366.
129. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Annaert W, De Strooper B, Saftig P. 2001a. Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem 276:42645-42657.
130. Wiltfang J, Esselmann H, Maler JM, Bleich S, Hüther G, Kornhuber J. 2001b. Molecular biology of Alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology 47:65-71.
131. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J. 2002. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 81:481-496.
132. Zetterberg H, Wahlund LO, Blennow K. 2003. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352:67-69.
133. Zetterberg H, Andreasen N, Blennow K. 2004. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. Neurosci Lett 367:194-196.
134. Zhou G, Miura Y, Shoji H, Yamada S, Matsuishi T. 2001. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease. J Neurol Neurosurg Psychiatry 70:229-231.